Therefore, based on previous studies of our work group, the use of a pharmacological combination based on Doxorubicin/Metformin/Sodium Oxamate (3Tx) was proposed, which has demonstrated antitumor effectiveness in several in vitro and in vivo models of breast and colorectal cancer through the inhibition of PI3K/Akt/mTOR/HIF-1α signaling [27,28,29]. Here, MTOR is linked to colorectal cancer.